Compare Amcor PLC (AMCR) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amcor PLC vs Crispr Therapeutics AG — how do they compare? Amcor PLC trades at $43 (market cap $19.96B), while Crispr Therapeutics AG trades at $53.25 (market cap $5.25B). The key difference: Amcor PLC is far larger — about 3.8× Crispr Therapeutics AG's market cap, and Amcor PLC pays a 6.02% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| AMCR | CRSP | |
|---|---|---|
Market Cap | $19.96B | $5.25B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $76.78 |
52-Week Low | $36.69 | $44.34 |
Enterprise Value | $35.08B | $3.60B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $43.18, up 1.12% today, with a bullish technical outlook and strong analyst consensus. The stock shows consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. Recent news highlights expansion in China and sustainable packaging partnerships, supporting growth prospects amid investor optimism.
The outlook for AMCR is positive, driven by earnings momentum and strategic initiatives, but risks include margin pressure and integration challenges from the Berry acquisition. With a consensus price target of $45.75, upside potential exists, though investors should monitor debt levels and competitive pressures in the packaging sector.
CRISPR Therapeutics (CRSP) trades at $53.35, down 5.31% on the day, with technical indicators showing a bullish trend but mixed earnings performance. The company maintains strong analyst support with a $74.50 consensus price target, despite negative profitability metrics and recent quarterly misses. Recent FDA pediatric approval for Casgevy expands its market potential, though cash flow remains challenged by high operational costs.
Outlook is cautiously optimistic driven by gene-editing leadership and clinical catalysts, but investment carries high risk due to persistent losses, volatile cash flows, and competitive pressures. Upside depends on successful commercialization and pipeline execution, while downside risks include funding needs and regulatory hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
